Recent Updates — KPHMW

Kiora Pharmaceuticals appointed Keith Lane as Executive Vice President, Head of Clinical Development and Regulatory Affairs, effective September 8, 2026. Lane brings over 20 years of ophthalmology experience, previously serving as Chief Scientific Officer at Ora, Inc., where he oversaw clinical operations for more than 60 trials, including 12 global Phase 3 studies supporting three new drug applications. His compensation includes a $350,000 annual base salary, a $75,000 sign-on bonus, and a performance bonus target of up to 35% of his base salary. He will also receive an option to purchase 55,000 shares under the Company’s 2024 Equity Incentive Plan, vesting one-third after one year and monthly thereafter over two years. Lane will lead U.S. and global clinical development for Kiora's pipeline, including KIO-301 for retinitis pigmentosa. Kiora Pharmaceuticals is a clinical-stage biotechnology company developing small molecule therapies for retinal diseases.

Kiora Pharmaceuticals entered into an exclusive license agreement with Chong Kun Dang Pharmaceutical Corporation (CKD) for the development and commercialization of its KIO-301 product in South Korea. The deal includes a $1 million upfront payment, potential milestone payments, and double-digit royalties on net sales. CKD will lead local activities while coordinating with existing partners Laboratoires Théa and Senju Pharmaceutical for a global Phase 3 trial for retinitis pigmentosa. This agreement completes Kiora's major regional partnerships for KIO-301 across the U.S., Europe, Japan, China, and South Korea. The company will redirect internal resources to advance its KIO-104 pipeline and evaluate other therapeutic applications. Kiora Pharmaceuticals is a clinical-stage biotechnology company developing advanced therapies for retinal disease.

Kiora Pharmaceuticals reported second quarter 2026 financial results and provided clinical updates. The company ended the quarter with approximately $16.8 million in cash and short-term investments, providing an operating runway into late 2028. Net loss was approximately $2.1 million, compared to a net loss of $2.2 million in the prior year period. Research and development expenses were approximately $2.1 million before recognizing $1.3 million in reimbursable collaboration credits from Théa Open Innovation. The company secured a private placement for up to $24.0 million in gross proceeds, including $5.0 million received upfront. Clinically, Kiora advanced enrollment in the Phase 2 ABACUS-2 trial of KIO-301 into the higher-dose cohort and continued enrollment in the Phase 2 KLARITY trial of KIO-104. The company operates as a clinical-stage biotechnology firm developing small-molecule therapies for retinal diseases.